146 related articles for article (PubMed ID: 22305998)
1. Aliskiren-based dual- and triple-combination therapies in high-risk US minority patients with stage 2 hypertension.
Ferdinand KC; Weitzman R; Purkayastha D; Sridharan K; Jaimes EA
J Am Soc Hypertens; 2012; 6(3):219-27. PubMed ID: 22305998
[TBL] [Abstract][Full Text] [Related]
2. Clinic and ambulatory blood pressure lowering effect of aliskiren/amlodipine/hydrochlorothiazide combination in patients with moderate-to-severe hypertension: a randomized active-controlled trial.
Lacourcière Y; Taddei S; Konis G; Fang H; Severin T; Zhang J
J Hypertens; 2012 Oct; 30(10):2047-55. PubMed ID: 22828090
[TBL] [Abstract][Full Text] [Related]
3. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of aliskiren-based dual and triple combination therapies in US minority patients with stage 2 hypertension.
Ferdinand KC; Weitzman R; Israel M; Lee J; Purkayastha D; Jaimes EA
J Am Soc Hypertens; 2011; 5(2):102-13. PubMed ID: 21414565
[TBL] [Abstract][Full Text] [Related]
5. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide.
Schmieder RE; Philipp T; Guerediaga J; Gorostidi M; Smith B; Weissbach N; Maboudian M; Botha J; van Ingen H
Circulation; 2009 Jan; 119(3):417-25. PubMed ID: 19139391
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double-blind, multifactorial study.
Littlejohn TW; Jones SW; Zhang J; Hsu H; Keefe DL
J Hum Hypertens; 2013 May; 27(5):321-7. PubMed ID: 23076450
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension and obesity or metabolic syndrome.
Weinberger MH; Izzo JL; Purkayastha D; Weitzman R; Black HR
J Am Soc Hypertens; 2011; 5(6):489-97. PubMed ID: 21925996
[TBL] [Abstract][Full Text] [Related]
8. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.
Villamil A; Chrysant SG; Calhoun D; Schober B; Hsu H; Matrisciano-Dimichino L; Zhang J
J Hypertens; 2007 Jan; 25(1):217-26. PubMed ID: 17143194
[TBL] [Abstract][Full Text] [Related]
9. Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study.
Drummond W; Sirenko YM; Ramos E; Baek I; Keefe DL
Am J Cardiovasc Drugs; 2011 Oct; 11(5):327-33. PubMed ID: 21846154
[TBL] [Abstract][Full Text] [Related]
10. Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study.
Lacourcière Y; Wright JT; Samuel R; Zappe D; Purkayastha D; Black HR;
Blood Press Monit; 2009 Jun; 14(3):112-20. PubMed ID: 19384192
[TBL] [Abstract][Full Text] [Related]
11. Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: Secondary analyses evaluating efficacy and safety.
Calhoun DA; Crikelair NA; Yen J; Glazer RD
Adv Ther; 2009 Nov; 26(11):1012-23. PubMed ID: 20024680
[TBL] [Abstract][Full Text] [Related]
12. Comparison of aliskiren/hydrochlorothiazide combination therapy and amlodipine monotherapy in patients with stage 2 systolic hypertension and type 2 diabetes mellitus.
Townsend RR; Forker AD; Bhosekar V; Yadao A; Keefe DL
J Clin Hypertens (Greenwich); 2011 Dec; 13(12):889-97. PubMed ID: 22142348
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the dose--response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension.
Puig JG; Schunkert H; Taylor AA; Boye S; Jin J; Keefe DL
Clin Ther; 2009 Dec; 31(12):2839-50. PubMed ID: 20110023
[TBL] [Abstract][Full Text] [Related]
15. Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
Jordan J; Engeli S; Boye SW; Le Breton S; Keefe DL
Hypertension; 2007 May; 49(5):1047-55. PubMed ID: 17353513
[TBL] [Abstract][Full Text] [Related]
16. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial.
Schmieder RE; Philipp T; Guerediaga J; Gorostidi M; Bush C; Keefe DL
J Hypertens; 2009 Jul; 27(7):1493-501. PubMed ID: 19444142
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial.
Andersen K; Weinberger MH; Egan B; Constance CM; Ali MA; Jin J; Keefe DL
J Hypertens; 2008 Mar; 26(3):589-99. PubMed ID: 18300872
[TBL] [Abstract][Full Text] [Related]
18. Aliskiren/amlodipine vs. aliskiren/hydrochlorothiazide in hypertension: indirect meta-analysis of trials comparing the two combinations vs. monotherapy.
Liu Y; Yan R; Song A; Niu X; Cao C; Wei J; Dong X; Gao D
Am J Hypertens; 2014 Feb; 27(2):268-78. PubMed ID: 24304656
[TBL] [Abstract][Full Text] [Related]
19. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults.
Pool JL; Glazer R; Weinberger M; Alvarado R; Huang J; Graff A
Clin Ther; 2007 Jan; 29(1):61-73. PubMed ID: 17379047
[TBL] [Abstract][Full Text] [Related]
20. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
